Linked Life Data

19836953

Source:http://linkedlifedata.com/resource/pubmed/id/19836953

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-11-30
pubmed:abstractText
Chemotherapeutic agents have dominated neoadjuvant treatment compared to endocrine agents in the past and have demonstrated their ability to produce tumour shrinkage to allow breast conservation. However, in the more recent setting, studies have been emerging with the use of aromatase inhibitors, especially comparing its use with tamoxifen in selected group of patients. The role of tamoxifen in its ability to achieve tumour shrinkage has been evaluated in the past, and has shown to produce slow but sustained response. Aromatase inhibitors have shown superiority over tamoxifen in adjuvant and metastatic setting, and the aim of our study was to compare their outcome with regard to response and breast conservation in the neoadjuvant setting. We also looked into optimum duration of neoadjuvant treatment and also the role of pathological complete response as a surrogate marker for clinical outcome. Our review highlights the superiority of aromatase inhibitors over tamoxifen in the neoadjuvant setting and even challenges chemotherapy with regard to response in selected group of patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1532-3080
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
339-44
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
pubmed:affiliation
Division of Breast Surgery, Nottingham City Hospital, Nottingham, UK. john.mathew@nottingham.ac.uk
pubmed:publicationType
Journal Article, Comparative Study, Review